#United States #San Diego #Alnylam Pharmaceuticals #Genomic Discovery #RNAi Therapeutics

Alnylam Pharmaceuticals Joins Alliance for Genomic Discovery

Alnylam Pharmaceuticals, a pioneering company in RNA interference (RNAi) therapeutics, has recently joined the Alliance for Genomic Discovery (AGD). This collaboration marks a significant step in enhancing the development of precision medicine through a more comprehensive clinical genomic dataset. Together with Illumina and Nashville Biosciences, Alnylam aims to leverage these genetic insights to discover new drug targets and advance therapeutic innovations.

The AGD is designed to accelerate pharmaceutical research and development by utilizing a vast array of clinical genomic data. With Alnylam as its ninth member, the alliance includes notable companies such as AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk. The inclusion of Alnylam not only strengthens AGD's participation in the genomic research community, but also broadens its capabilities by adding a new set of 31,250 whole genomes to the already existing cohort of 250,000 whole-genome sequences.

Advancements in Drug Discovery

Alnylam's participation in the AGD is particularly crucial because RNAi therapeutics focus on the